Nationwide study reveals persistent diagnostic delays, specialist access barriers, and unmet psychosocial needs among Americans living with steatotic liver disease

NOVEMBER 5, 2025, Boise, IDAHO –  The Fatty Liver Foundation (FLF) will present findings from its State of Steatotic (Fatty) Liver Care in America: 2022–2025 Patient Perspectives Research at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, DC. The abstract, titled “Shifting Trends in U.S. Steatotic Liver Disease Care: Patient-Reported Insights from the 2022–2025 SLD Care Survey” (Publication No. 2592), will be presented as part of the MASLD/MASH – Epidemiology and Natural History, Prevention and Outcomes poster session Saturday, November 8, 2025, from 8:00 AM to 5:00 PM at the Walter E. Washington Convention Center.

NOVEMBER 3, 2025, Boise, IDAHO – The Fatty Liver Foundation (FLF) will have a major presence at this year’s American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM) in Washington, D.C., November 7–11, 2025. FLF will introduce the inaugural cohort of Fellows of the Dr. Stephen A. Harrison Patient Advocacy Fellowship, present two scientific posters, host three Community Conversations, and participate in several sessions as part of AASLD’s Patient Programming.

Fellowship elevates patient voices to ensure lived experience informs global decisions on MASH drug and diagnostic development

SEPTEMBER 10, 2025, BOISE, IDAHO, USA — The Fatty Liver Foundation (FLF) announced that the Dr. Stephen A. Harrison Patient Advocacy Fellowship will be introduced today at the Liver Forum 19 Meeting in Paris, France, to an international audience of regulators, academic leaders, innovators in MASH drug and diagnostic development, and patient advocates.

Twenty Fellows Selected to Carry Forward Dr. Harrison’s Legacy Through Patient-Centered Advocacy and Leadership

SEPTEMBER 2, 2025, BOISE, IDAHO, USA — The Fatty Liver Foundation (FLF) is proud to announce the inaugural cohort of the Dr. Stephen A. Harrison Patient Advocacy Fellowship, a first-of-its-kind training program that equips patients and patient advocates with the knowledge and tools to meaningfully shape the future of drug and diagnostic development for metabolic dysfunction-associated steatohepatitis (MASH) and other forms of steatotic liver disease.

New Fellowship Equips Liver Disease Advocates to Shape the Future of MASH Research and Policy

JUNE 12, 2025, BOISE, IDAHO, USA — The Fatty Liver Foundation (FLF) today announced the launch of the Dr. Stephen A. Harrison Patient Advocacy Fellowship, the first-of-its-kind program designed to elevate the role of patient advocates in the advancement of care, research, and policy for metabolic dysfunction-associated steatohepatitis (MASH) and other phenotypes of steatotic liver disease (SLD). The launch coincides with Global Fatty Liver Day, a global awareness initiative promoting early detection and action on liver disease.

MAY 6, 2025; BOISE, IDAHO — The Fatty Liver Foundation (FLF), in partnership with the French-American Piano Society, is proud to announce a special benefit piano recital featuring internationally acclaimed pianist Célimène Daudet, on October 23, 2025, at La Maison Française within the Embassy of France in Washington, DC.

April 16, 2025; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the launch of the fourth annual "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research", a nationwide survey designed to capture the lived experiences of individuals affected by metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-associated forms of steatotic liver disease.

Fatty Liver Foundation Supports Biden-Harris Administration Proposal to Expand Coverage for Anti-Obesity Medications

November 26, 2024; Boise, IDAHO —Today, the Fatty Liver Foundation (FLF) applauds the Biden-Harris Administration for proposing a landmark rule to expand Medicare and Medicaid coverage for anti-obesity medications (AOMs). This bold step acknowledges obesity as a chronic disease and aims to provide millions of Americans with access to life-changing treatments that improve health outcomes and reduce healthcare costs.

Fatty Liver Foundation to Present New Findings Expanding Understanding of Steatotic Liver Disease Patient Experiences at AASLD The Liver Meeting® 2024

November 7, 2024; Boise, IDAHO — The Fatty Liver Foundation (FLF) will present new insights into the evolving experiences of individuals with Steatotic Liver Disease (SLD), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Alcohol-Associated Liver Disease (ALD), at this year’s The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM), held from November 15-19 in San Diego, California. The poster presentation, titled "Evolution of MASLD/MASH Patient Experiences: Insights from ‘The State of Steatotic (Fatty) Liver Care in America’ Surveys 2022-2024" (Abstract Number: 2299), provides a comprehensive look at patient-reported challenges, access to care, and progress in SLD management across the U.S.